Globus Medical, Inc. (GMED) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong growth in key business areas like trauma and neuromonitoring, and an increase in adjusted gross profit. Despite a decline in enabling technologies revenue, the company shows resilience and strategic focus on product development and market expansion. The Q&A section indicates analysts' confidence in the management's strategy, despite some uncertainties. The reaffirmation of revenue guidance and positive developments in product portfolio and international markets support a positive sentiment, likely leading to a stock price increase.
Key Financial Performance
Sales $769 million, growing 22.9% year-over-year. Growth driven by U.S. Spine business, international spine, trauma, and neuromonitoring.
Non-GAAP Diluted Earnings Per Share $1.18, growing 42.6% year-over-year. Growth attributed to revenue growth, operational synergies, and Nevro acquisition.
Free Cash Flow $213.9 million, a record for the third quarter. Growth driven by operational efficiencies and revenue growth.
Base Business Revenue $669.8 million, growing 7% as reported and 7.1% day adjusted year-over-year. Growth driven by U.S. and international spine businesses.
Nevro Business Revenue $99.3 million, contributing to overall growth. Sequential growth of 4.9% from the previous quarter.
Adjusted EBITDA Margins (Base Globus Business) 35.3%, growing 435 basis points year-over-year. Growth driven by operational leverage and cost synergies.
Adjusted EBITDA Margins (Nevro Business) 16.2%, showing improvement from negative margins in prior quarters.
U.S. Spine Business Revenue Growth of 9.6% year-over-year. Growth driven by competitive recruiting and product portfolio expansion.
Enabling Technologies Revenue $28 million, declining 27% year-over-year. Decline attributed to lower sales of EGPS systems.
International Spine Business Revenue Growth of 5.6% as reported and 6% day adjusted year-over-year. Growth driven by markets in EMEA, Asia Pacific, and Latin America.
Trauma Business Revenue Growth of 17.2% year-over-year. Growth driven by overcoming manufacturing challenges and portfolio expansion.
Neuromonitoring Business Revenue Growth of 15.8% year-over-year. Growth attributed to overcoming reimbursement headwinds from mid-2024.
Adjusted Gross Profit 68.1%, up from 66.5% year-over-year. Growth driven by favorable sales mix and synergy execution.
Operating Cash Flow $249.7 million, driven by sales growth and working capital improvements.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ExcelsiusXR launch: Introduced a wearable extended reality navigation headset to enhance surgeon focus and workflow ergonomics.
ExcelsiusGPS instruments: Received FDA 510(k) clearance for new instruments compatible with interbody fusion devices, enhancing the Excelsius platform.
ANTHEM plating line expansion: Launched a comprehensive elbow plating system, achieving 80%+ portfolio match with competitors.
Eflex robotic system: Demonstrated ease of use and accuracy in TKA procedures, with plans to expand procedural applications to hip by 2026.
U.S. Spine business: Achieved 9.6% growth, marking 32 consecutive weeks of growth and strong competitive recruiting.
International Spine business: Grew 5.6% as reported, with notable contributions from EMEA, Asia Pacific, and LatAm regions.
Trauma business: Delivered 17.2% growth, marking its highest quarterly revenue since inception.
Nevro acquisition impact: Contributed $99.3 million in revenue, showing sequential growth and integration progress.
Profitability improvements: Adjusted gross margins and EBITDA margins improved significantly, with base Globus business achieving 35.3% EBITDA margin.
Free cash flow: Generated a record $213.9 million in Q3, driven by operational efficiencies and synergy realization.
Capital allocation: Repurchased $40 million in shares during Q3, totaling $256 million year-to-date.
Market penetration strategy: Focused on surgeon conversions, sales force expansion, and operational excellence to drive growth.
Nevro integration: Achieved accretive earnings in 2025, earlier than expected, through cost structure optimization and sales growth.
Capital placement strategy: Enhanced flexibility in capital deal structures to drive spinal implant growth and operationalize capital acquisition.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Enabling Technologies revenue decline: Revenue from Enabling Technologies declined by 27% compared to the prior year quarter, primarily due to lower sales of EGPS systems. This indicates challenges in closing sales at the same pace as in previous years, which could impact overall revenue growth.
International supply chain constraints: Supply chain prioritization for the U.S. market has impacted inventory availability in international markets, potentially limiting growth opportunities in these regions.
Litigation charges: The company incurred onetime net charges for estimated litigation of $28.3 million, which increased SG&A expenses and could pose financial risks if such charges recur.
Nevro integration challenges: While progress has been made, integration activities for the recently acquired Nevro business are ongoing, with potential risks related to supply chain centralization and production activities.
Decline in enabling technology sales: Lower enabling technology sales of $10.3 million were noted, which could affect the company's ability to maintain its competitive edge in this segment.
Capital acquisition challenges: The company is facing challenges in operationalizing capital acquisition processes, moving away from traditional CapEx models, which could delay capital placements and impact implant sales growth.
R&D expense reduction: Synergy actions have led to reduced R&D expenses, which, while improving short-term financials, could impact long-term innovation and product development.
International growth limitations: Despite growth in international markets, supply chain constraints and prioritization of U.S. inventory could limit the ability to fully capitalize on international opportunities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has updated its 2025 net sales guidance to be in the range of $2.86 billion to $2.9 billion, an increase from the previous range of $2.8 billion to $2.9 billion. This implies growth over 2024 ranging from 13.5% to 15.1%.
Earnings Per Share (EPS) Guidance: The 2025 fully diluted non-GAAP earnings per share guidance has been revised to between $3.75 and $3.85, up from the previous range of $3 to $3.30. This implies growth over 2024 ranging from 23.2% to 26.5%.
Gross Profit Margin: For 2025, the company expects total adjusted gross profit to be in the range of 67% to 68% of consolidated revenue.
Research and Development (R&D) Expenses: For 2025, R&D expenses are expected to be in the range of 5% to 5.5% of consolidated revenue.
Tax Rate: The full-year non-GAAP tax rate is expected to be approximately 24% to 25%.
Capital Allocation Strategy: The company plans to prioritize internal investments in product development, manufacturing, and sales infrastructure, while continuing share repurchases and evaluating complementary M&A opportunities.
Nevro Business Outlook: The Nevro business is now expected to be accretive to earnings in fiscal year 2025, earlier than the previous expectation of the second year of operations.
International Market Growth: The company sees long-term potential for international markets to grow revenue in the 10% to 15% range.
Trauma Business Growth: The trauma business is expected to continue its growth trajectory, supported by investments in manufacturing and product portfolio expansion.
Enabling Technologies Outlook: The company remains optimistic about the Enabling Technologies business, with a strong pipeline and plans to expand capital placement and operationalize capital acquisition models.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: We remained active with share repurchases, spending $40 million during the quarter, bringing our year-to-date repurchases to $256 million. Since 2020, share repurchases have been an important part of the Globus capital allocation strategy. From 2020 through the third quarter of 2025, we've spent $815 million to repurchase 14.5 million shares at an average price of $56. On average, we've spent $136 million per year to repurchase 2.4 million shares. Since Q3 2023, we repurchased $566 million or 9.5 million shares, representing approximately 1/4 of the deal dilution. Share repurchases remain an integral part of our capital allocation strategy as we seek to first prioritize internal investment in innovative product development efforts, build sets for our sales personnel across the globe and increase our manufacturing footprint through CapEx. Secondarily, we seek to opportunistically repurchase shares as we demonstrate our confidence in the business and our commitment to creating long-term value for our shareholders.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is driving the strength and acceleration in U.S. Core Spine, and how sustainable is it?
A:The strength is broad across all categories in spine, including expandables, pedicle screws, and DuraPro drills. Growth is primarily from the core implant business, supported by robotic pull-through, new product launches, and competitive rep acquisitions. Management is focused on continuing this growth and differentiation.
Q:What does the shift to operating leases mean for future revenue and strategy?
A:Historically, robots were sold as cash sales, but there is now an increase in demand for alternative acquisition methods like pay-per-click models or fair market value leases. This changes revenue recognition to a longer-term model (3-5 years). Management sees this as a shift in the business model but did not provide specific guidance on its impact.
Q:What are the expectations for Nevro's margin progression over the next 12-18 months?
A:Nevro's Q3 EBITDA margin was 16.2%. Management is focused on integrating the business, reducing redundant spending, and driving new product development. They aim to grow the sales force and improve efficiency, targeting gross margins of 67-68% and reducing SG&A OpEx from 49% of sales.
Q:How is Q4 growth in the enabling tech business expected to perform?
A:Management is confident in the overall guidance but did not provide specific details for Q4. They noted a strong pipeline and the goal of driving long-term implant growth, service revenue, and disposable revenue.
Q:What is the strategy for expanding Nevro's product portfolio?
A:Nevro is primarily a spinal cord stimulation business. Management plans to explore areas like peripheral nerve, diabetic neuropathy, and Parkinson's tremors. These developments will take time and are not immediate.
Q:What is the impact of shifting to more flexible payment models for robotics?
A:There has been an increase in leases and rentals, but they are not yet over 50% of deals. Management noted that flexible payment options might have slowed some deals but emphasized a strong pipeline.
Q:What progress has been made in improving Nevro's margins?
A:Initial cost reductions were achieved in R&D and SG&A by eliminating redundancies and focusing on efficiency. Future improvements will target gross margins and further SG&A reductions, aiming for mid-70s gross profit by 2026.
Q:What are the expectations for core Spine, Nevro, trauma, and recon growth into 2026?
A:Management is optimistic about the U.S. Spine market and expects international business to grow 10-15% beyond 2025. Trauma is recovering from manufacturing challenges, and Nevro shows early positive signs, but management remains cautious about long-term projections.
Q:What are hospitals' reasons for slower decision-making on robotics purchases?
A:Hospitals are reviewing all available robotic offerings, focusing on ASC growth, and reallocating funds to other priorities. Flexible payment options like operational leases are being offered to address these challenges.
Q:What is the outlook for Nevro's top-line growth?
A:Management is cautious about projecting long-term growth but noted sequential positive growth between Q2 and Q3. They are focused on integration and competitive rep additions.
Q:What is the status of the legacy trauma portfolio?
A:The portfolio is at critical mass, covering 80% of competitors' offerings. Management is focused on a density model targeting Level 1 and Level 2 trauma centers.
Q:What is the competitive position of Simplify in the market?
A:Simplify has 2-level approval and is gaining market share. Management did not provide further details on its competitive position.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance or detailed answers on several topics, including the exact impact of the shift to operating leases on future revenue, detailed Q4 growth expectations for enabling tech, long-term projections for Nevro's top-line growth, and specific competitive positioning of Simplify.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Australia
ED
EFlex
EGPS
ExcelsiusGPS instrument
ExcelsiusHub
Globus Medical
Modulus
President CEO
Spine
TLIF
ability
activity
attention
cadence
change
contract
day Japan
ease use
expansion
flexibility
focus
geography
interbody
inventory delivery
laser
navigation
objective
overarching goal
plating
profile
quality
region
service
stickiness
surgeon conversion
surgeon desire
talent
week
workflow
GMED Transcript
Globus Medical, Inc. (GMED) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary indicates strong financial performance, with a 10% revenue increase and improved operating income and EPS. Despite a slight decrease in gross margin, overall financial health appears robust. The absence of strategic updates or risks discussed suggests no immediate concerns. The Q&A section did not reveal any analyst dissatisfaction. Given these factors, the stock price is likely to experience a positive movement, though not dramatically so, due to the lack of additional catalysts or market cap data.
Globus Medical, Inc. (GMED) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call summary shows strong financial performance with significant year-over-year growth in revenue, gross margin, operating income, and net income. The increase in revenue guidance and EPS guidance for 2025 further supports a positive outlook. The absence of explicit or implied risks and the lack of negative sentiment in the Q&A section also contribute to the positive sentiment. However, the lack of discussion on shareholder returns and operational updates prevents a 'Strong positive' rating.
Kinaxis Inc. (KXS:CA) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reveals strong financial performance, product development, and market strategy, with positive growth in revenue and free cash flow. The Q&A highlights optimism in AI integration and market expansion, despite some uncertainties in monetization guidance. The reaffirmed revenue guidance and robust pipeline support a positive sentiment. The lack of specific guidance on certain metrics is a minor concern, but overall, the company's strategic initiatives and operational improvements suggest a positive outlook.
Globus Medical, Inc. (GMED) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reveals strong growth in key business areas like trauma and neuromonitoring, and an increase in adjusted gross profit. Despite a decline in enabling technologies revenue, the company shows resilience and strategic focus on product development and market expansion. The Q&A section indicates analysts' confidence in the management's strategy, despite some uncertainties. The reaffirmation of revenue guidance and positive developments in product portfolio and international markets support a positive sentiment, likely leading to a stock price increase.
GMED Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
